Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rik Ossenkoppele

Showing results (1-10 of 310) with videos related to

Pageof 31
Sort By:
Nature Medicine|December 5, 2018
Genetic characterization of amyloid-β and tau network spreadRik Ossenkoppele, Oskar Hansson
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2021
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's diseaseRik Ossenkoppele, Oskar Hansson
JAMA Neurology|April 29, 2024
Fluid Biomarker Changes After Amyloid-β-Targeting DrugsRik Ossenkoppele, Charlotte E Teunissen
Brain : a Journal of Neurology|May 16, 2024
The implications of amyloid-β pathology: only time will tellEmma M Coomans, Rik Ossenkoppele
JAMA Neurology|October 4, 2017
The Complexity of Subjective Cognitive DeclineRik Ossenkoppele, William J Jagust
Brain : a Journal of Neurology|June 21, 2022
Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?Colin Groot, Henne Holstege, Rik Ossenkoppele
JAMA Neurology|November 6, 2023
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-βRik Ossenkoppele, Wiesje M van der Flier
Alzheimer Disease and Associated Disorders|January 16, 2018
Evidence-based Interpretation of Amyloid-β PET Results: A Clinician's ToolDavid Bergeron, Rik Ossenkoppele, Robert Jr Laforce
The Lancet. Neurology|June 1, 2022
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trialsRik Ossenkoppele, Rik van der Kant, Oskar Hansson
JAMA|September 16, 2015
Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk--ReplyWillemijn J Jansen, Rik Ossenkoppele, Pieter Jelle Visser
Pageof 31

Showing results (1-10 of 310) with videos related to

Sort By:
Pageof 31
Nature Medicine|December 5, 2018
Genetic characterization of amyloid-β and tau network spreadRik Ossenkoppele, Oskar Hansson
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 13, 2021
Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's diseaseRik Ossenkoppele, Oskar Hansson
JAMA Neurology|April 29, 2024
Fluid Biomarker Changes After Amyloid-β-Targeting DrugsRik Ossenkoppele, Charlotte E Teunissen
Brain : a Journal of Neurology|May 16, 2024
The implications of amyloid-β pathology: only time will tellEmma M Coomans, Rik Ossenkoppele
JAMA Neurology|October 4, 2017
The Complexity of Subjective Cognitive DeclineRik Ossenkoppele, William J Jagust
Brain : a Journal of Neurology|June 21, 2022
Do genetic factors contribute to sex-specific differences in resilience to amyloid pathology?Colin Groot, Henne Holstege, Rik Ossenkoppele
JAMA Neurology|November 6, 2023
APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-βRik Ossenkoppele, Wiesje M van der Flier
Alzheimer Disease and Associated Disorders|January 16, 2018
Evidence-based Interpretation of Amyloid-β PET Results: A Clinician's ToolDavid Bergeron, Rik Ossenkoppele, Robert Jr Laforce
The Lancet. Neurology|June 1, 2022
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trialsRik Ossenkoppele, Rik van der Kant, Oskar Hansson
JAMA|September 16, 2015
Amyloid Pathology, Cognitive Impairment, and Alzheimer Disease Risk--ReplyWillemijn J Jansen, Rik Ossenkoppele, Pieter Jelle Visser
Pageof 31